For instance, anti‐epidermal growth factor receptor (EGFR) antibodies significantly improve the survival of patients with metastatic CRC (mCRC) (Lievre et al, 2006, 2008); however, only patients with wild‐type RAS CRC (40% of cases) may hope to benefit from this treatment. Here, EGFR is linked to colorectal carcinoma.